KBC Securities - ONWARD MEDICAL NV (ONWD) Onward Medical € 50m equity raise from Ottobock and institutional investors

Report

KBC Securities

Jacob Mekhael ...

Thomas Vranken

Onward Medical € 50m equity raise from Ottobock and institutional investors

Last week, Onward announced an upsized € 50m capital increase, which included a € 22.5m ticket from Ottobock, a global player in the fields of prosthetics, orthotics and exoskeleton technology, as new cornerstone investor. The new shares were issued at € 5.00 p.s., representing a 12.6% discount vs. last closing price before deal announcement. We resume our coverage with a € 9.1 TP and Buy rating (from Suspended).

29/10/2024 1 EN

Underlying

ONWARD MEDICAL NV

See profile

NL0015000HT4 Euronext Brussels Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Thomas Vranken

Other Reports on these Companies

KBC Securities

Morning Notes : ACKB BB, CRBN NA, GIMB BB, IBAB BB, MONT BB, SHUR BB, ONWD BB

: ACKB BB, CRBN NA, GIMB BB, IBAB BB, MONT BB, SHUR BB, ONWD BB

19h / 29m 19h / 29m 1 EN

GlobeNewsWire

ONWARD® Medical Publishes Closing of Bookbuild Offering

ONWARD® Medical Publishes Closing of Bookbuild Offering THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Oct. 28, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today the closing of its previously announced private placement with institutional ...

October 28, 2024 October 28, 2024 1 EN

Corbion Conference call feedback

Below are the highlights of the conference call. 3Q24 adj EBITDA jumped by 44% and was c. 4% above our estimate and 5% above consensus, supported by cost savings and an acceleration of organic growth. FY adj EBITDA growth guidance is upped from >18% to 22-25% which seems conservative with our and consensus forecasts even higher (at +30% and +28%). Although the recent track record has been more volatile than expected, the strategic choices made recently (sticking to PLA, a disciplined investment approach on Algae, a much increased FCF focus) make sense. We appreciate Corbion for its leading pos...

16h / 22m 16h / 22m 1 EN

Wim Hoste

Wim Hoste

Corbion FIRST LOOK: 3Q EBITDA +44%, FY guidance upped but still looks cautious

3Q24 adj EBITDA jumped by 44% and was c. 4% above our estimate and 5% above consensus, supported by cost savings and an acceleration of organic growth. FY adj EBITDA growth guidance is upped from >18% to 22-25% which seems conservative with our and consensus forecasts even higher (at +30% and +28%). Although the recent track record has been more volatile than expected, the strategic choices made recently (sticking to PLA, a disciplined investment approach on Algae, a much increased FCF focus) make sense. We appreciate Corbion for its leading position in lactic acid and consider valuation to be...

19h / 15m 19h / 15m 1 EN

Jacob Mekhael ... (+6)

Jacob Mekhael
Lynn Hautekeete
Michiel Declercq
Sharad Kumar S.P
Thomas Vranken
Wim Hoste

Morning Notes : ACKB BB, CRBN NA, GIMB BB, IBAB BB, MONT BB, SHUR BB, ONWD BB

: ACKB BB, CRBN NA, GIMB BB, IBAB BB, MONT BB, SHUR BB, ONWD BB

19h / 29m 19h / 29m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Onward Medical € 50m equity raise from Ottobock and institutional investors

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : ACKB BB, CRBN NA, GIMB BB, IBAB BB, MONT BB, SHUR BB, ONWD BB

ONWARD® Medical Publishes Closing of Bookbuild Offering

Corbion Conference call feedback

Corbion FIRST LOOK: 3Q EBITDA +44%, FY guidance upped but still looks cautious

Morning Notes : ACKB BB, CRBN NA, GIMB BB, IBAB BB, MONT BB, SHUR BB, ONWD BB

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe